INNATE PHARMA SA (IPH.PA) Forecast, Price Target & Analyst Ratings

EPA:IPH • FR0010331421

Current stock price

1.162 EUR
-0.01 (-0.68%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INNATE PHARMA SA (IPH.PA).

Forecast Snapshot

Consensus Price Target

Price Target
€6.27
+ 439.85% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q2 / 2026
EPS Estimate
-€0.07
Revenue Estimate
7.817M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.50%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
€6.27
Upside
+ 439.85%
From current price of €1.16 to mean target of €6.27, Based on 8 analyst forecasts
Low
€6.16
Median
€6.27
High
€6.51

Price Target Revisions

1 Month
0.00%
3 Months
25.59%

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for IPH.PA. The average price target is 6.27 EUR. This implies a price increase of 439.85% is expected in the next year compared to the current price of 1.162.
The average price target has been revised upward by 25.59% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

IPH Current Analyst RatingIPH Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4

Analyst Ratings History

IPH Historical Analyst RatingsIPH Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
82.50%
IPH.PA was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about IPH.PA.
In the previous month the buy percentage consensus was at a similar level.
IPH.PA was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q2 / 2026
EPS Estimate
-€0.07
Revenue Estimate
7.817M
Revenue Q2Q
367.80%
EPS Q2Q
72.00%
Number of Analysts
2

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
IPH.PA revenue by date.IPH.PA revenue by date.
51.901M
4.68%		12.622M
-75.68%		2.787M
-77.92%		25.319M
808.47%		15.809M
-37.56%		57.68M
264.86%		195.72M
239.32%		172.79M
-11.72%		224.02M
29.65%		263.64M
17.69%		440.9M
67.24%
EBITDA
YoY % growth
IPH.PA ebitda by date.IPH.PA ebitda by date.
-7.578M
-126.15%		-49.581M
-554.28%		-52.624M
-6.14%		144.43M
374.46%		192.91M
33.57%		N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
IPH.PA ebit by date.IPH.PA ebit by date.
-12.669M
22.87%		-51.575M
-307.10%		-54.008M
-4.72%		34.614M
164.09%		-61.384M
-277.34%		-65.419M
-6.57%		42.009M
164.22%		65.393M
55.66%		105.74M
61.70%		134.71M
27.40%		N/A
Operating Margin
IPH.PA operating margin by date.IPH.PA operating margin by date.
-24.41%-408.61%-1,937.85%136.71%-388.28%-113.42%21.46%37.85%47.20%51.10%N/A
EPS
YoY % growth
IPH.PA eps by date.IPH.PA eps by date.
N/A
-169.82%		N/A
23.22%		N/A
-35.80%		-0.50
10.00%		-0.69
-38.38%		N/AN/AN/AN/AN/AN/A

All data in EUR

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.07
72.00%		-0.13
-8.33%		-0.10
16.67%		-0.13
76.13%		-0.13
-85.71%		-0.09
30.77%		-0.13
-30.00%
Revenue
Q2Q % growth		7.817M
367.80%		2.293M
15.81%		2.404M
-13.74%		2.353M
-15.66%		2.788M
-64.33%		9.878M
330.79%		6.989M
190.72%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-8.211M
67.71%		-13.645M
-6.13%		-16.17M
70.06%		-19.766M
-51.82%		-19.443M
-136.78%		-14.685M
-7.62%		-19.917M
-23.17%

All data in EUR

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

IPH.PA Yearly Revenue VS EstimatesIPH.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
IPH.PA Yearly EPS VS EstimatesIPH.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
30.73%
Revenue Next 5 Year
46.26%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

INNATE PHARMA SA / IPH.PA Forecast FAQ

Can you provide the average price target for INNATE PHARMA SA stock?

8 analysts have analysed IPH.PA and the average price target is 6.27 EUR. This implies a price increase of 439.85% is expected in the next year compared to the current price of 1.162.

What are the consensus estimates for IPH stock next earnings?

The consensus EPS estimate for the next earnings of INNATE PHARMA SA (IPH.PA) is -0.07 EUR and the consensus revenue estimate is 7.82M EUR.

Can you provide the expected long term growth rate for INNATE PHARMA SA stock?

The expected long term growth rate for INNATE PHARMA SA (IPH.PA) is 30.73%.